Federal Government Releases Proposed Guidance for Exercising “March-In” Rights Under the Bayh-Dole Act: Implications for Pharmaceutical and Medical Technology Companies

Start
On December 8, 2023, the National Institute of Standards and Technology (NIST) published a draft guidance document regarding the government’s exercise of “march-in” rights under the Bayh-Dole Act. The Bayh-Dole march-in rights apply solely to patents and patent applications supported with federal funding, and not to products themselves……
By: Goodwin
Previous Story

India’s Digital Personal Data Protection Act 2023 vs. the GDPR: A Comparison

Next Story

Biotech Companies Continue to Make Progress on ESG